Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 Sep;73(3):366–369.

A sensitive radioimmunoassay for circulating alpha-interferon in the plasma of healthy children and patients with measles virus infection.

S Shiozawa 1, N Yoshikawa 1, K Iijima 1, K Negishi 1
PMCID: PMC1541777  PMID: 3208448

Abstract

The mean circulating alpha-interferon of healthy children aged 2 to 13.5 yrs as measured by a radioimmunoassay was 0.119 +/- 0.031 ng/ml, which was significantly lower than that of young adults. Circulating alpha-interferon of children with measles virus infection aged 1 to 11 yrs, on their first visit to the hospital when they were fully symptomatic, was 0.095 +/- 0.035 ng/ml (n = 39). It was 0.105 +/- 0.070 ng/ml (n = 21) on their second visit, 7 to 10 days after their first visit when the patients were convalescent. The difference was statistically insignificant. It is concluded that immunoreactive circulating alpha-interferon is low in children and reaches maximum level in young adults, subsequently declining gradually with age. Immunoreactive circulating alpha-interferon, a possible reflection of endogenous alpha-interferon, does not change significantly by the infection of measles virus.

Full text

PDF
366

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARON S., DUBUY H. G., BUCKLER C. E., JOHNSON M. L. RELATIONSHIP OF INTERFERON PRODUCTION TO VIRUS GROWTH IN VIVO. Proc Soc Exp Biol Med. 1964 Nov;117:338–341. doi: 10.3181/00379727-117-29575. [DOI] [PubMed] [Google Scholar]
  2. Baron S., Buckler C. E., Friedman R. M., McCloskey R. V. Role of interferon during viremia. II. Protective action of circulating interferon. J Immunol. 1966 Jan;96(1):17–24. [PubMed] [Google Scholar]
  3. Buffet-Janvresse C., Hovanessian A. G. Enzyme markers for the presence of circulating interferon: 2-5A synthetase in blood lymphocytes and protein kinase in platelet-rich plasma. Proc Soc Exp Biol Med. 1984 Feb;175(2):169–175. doi: 10.3181/00379727-175-41783. [DOI] [PubMed] [Google Scholar]
  4. GRESSER I., DULL H. B. A VIRUS INHIBITOR IN PHARYNGEAL WASHINGS FROM PATIENTS WITH INFLUENZA. Proc Soc Exp Biol Med. 1964 Jan;115:192–196. doi: 10.3181/00379727-115-28867. [DOI] [PubMed] [Google Scholar]
  5. Green J. A., Charette R. P., Yeh T. J., Smith C. B. Presence of interferon in acute- and convalescent-phase sera of humans with influenza or influenza-like illness of undetermined etiology. J Infect Dis. 1982 Jun;145(6):837–841. doi: 10.1093/infdis/145.6.837. [DOI] [PubMed] [Google Scholar]
  6. Gresser I., Belardelli F., Maury C., Maunoury M. T., Tovey M. G. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J Exp Med. 1983 Dec 1;158(6):2095–2107. doi: 10.1084/jem.158.6.2095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gresser I., Tovey M. G., Maury C., Bandu M. T. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J Exp Med. 1976 Nov 2;144(5):1316–1323. doi: 10.1084/jem.144.5.1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hooks J. J., Jordan G. W., Cupps T., Moutsopoulos H. M., Fauci A. S., Notkins A. L. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum. 1982 Apr;25(4):396–400. doi: 10.1002/art.1780250406. [DOI] [PubMed] [Google Scholar]
  9. Hooks J. J., Moutsopoulos H. M., Geis S. A., Stahl N. I., Decker J. L., Notkins A. L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979 Jul 5;301(1):5–8. doi: 10.1056/NEJM197907053010102. [DOI] [PubMed] [Google Scholar]
  10. Kirchner H. The interferon system as an integral part of the defense system against infections. Antiviral Res. 1986 Jan;6(1):1–17. doi: 10.1016/0166-3542(86)90035-5. [DOI] [PubMed] [Google Scholar]
  11. PETRALLI J. K., MERIGAN T. C., WILBUR J. R. ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN. Lancet. 1965 Aug 28;2(7409):401–405. doi: 10.1016/s0140-6736(65)90755-5. [DOI] [PubMed] [Google Scholar]
  12. PETRALLI J. K., MERIGAN T. C., WILBUR J. R. CIRCULATING INTERFERON AFTER MEASLES VACCINATION. N Engl J Med. 1965 Jul 22;273:198–201. doi: 10.1056/NEJM196507222730405. [DOI] [PubMed] [Google Scholar]
  13. Panem S., Check I. J., Henriksen D., Vilcek J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol. 1982 Jul;129(1):1–3. [PubMed] [Google Scholar]
  14. Perussia B., Trinchieri G. Inactivation of natural killer cell cytotoxic activity after interaction with target cells. J Immunol. 1981 Feb;126(2):754–758. [PubMed] [Google Scholar]
  15. Preble O. T., Black R. J., Friedman R. M., Klippel J. H., Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science. 1982 Apr 23;216(4544):429–431. doi: 10.1126/science.6176024. [DOI] [PubMed] [Google Scholar]
  16. Ray C. G., Gravelle C. R., Chin T. D. Circulating interferon in infants and children with acute respiratory illness. J Pediatr. 1967 Jul;71(1):27–32. doi: 10.1016/s0022-3476(67)80226-9. [DOI] [PubMed] [Google Scholar]
  17. Saigo K., Shiozawa S., Shiozawa K., Wakuya J., Ueda K., Yamaguchi N., Shibata H., Masaoka T. Alpha-interferon treatment for adult T cell leukemia: low levels of circulating alpha-interferon and it's clinical effectiveness. Blut. 1988 Feb;56(2):83–86. doi: 10.1007/BF00633470. [DOI] [PubMed] [Google Scholar]
  18. Shiozawa S., Chihara K., Shiozawa K., Fujita T., Ikegami H., Koyama S., Kurimoto M. A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients. Clin Exp Immunol. 1986 Oct;66(1):77–87. [PMC free article] [PubMed] [Google Scholar]
  19. Targan S., Dorey F. Dual mechanism of interferon augmentation of natural killer cytotoxicity (NKCC). Ann N Y Acad Sci. 1980;350:121–129. doi: 10.1111/j.1749-6632.1980.tb20613.x. [DOI] [PubMed] [Google Scholar]
  20. WHEELOCK E. F., SIBLEY W. A. CIRCULATING VIRUS, INTERFERON AND ANTIBODY AFTER VACCINATION WITH THE 17-D STRAIN OF YELLOW-FEVER VIRUS. N Engl J Med. 1965 Jul 22;273:194–198. doi: 10.1056/NEJM196507222730404. [DOI] [PubMed] [Google Scholar]
  21. WHEELOCK E. F., SIBLEY W. A. INTERFERON IN HUMAN SERUM DURING CLINICAL VIRAL INFECTIONS. Lancet. 1964 Aug 22;2(7356):382–385. [PubMed] [Google Scholar]
  22. Waddell D. J., Wilbur J. R., Merigan T. C. Interferon production in human mumps infections. Proc Soc Exp Biol Med. 1968 Jan;127(1):320–324. doi: 10.3181/00379727-127-32681. [DOI] [PubMed] [Google Scholar]
  23. Ytterberg S. R., Schnitzer T. J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982 Apr;25(4):401–406. doi: 10.1002/art.1780250407. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES